No Data
Forte Biosciences Initiated at Buy by Brookline Capital
Forte Biosciences Initiated at Buy by Brookline Capital
Express News | Brookline Capital Initiates Coverage On Forte Biosciences With Buy Rating, Announces Price Target of $4
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. () (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as
Express News | CORRECTION: Forte Biosciences Q1 GAAP EPS $(0.16) Beats $(0.17) Estimate
Forte Biosciences | 10-Q: Quarterly report
Press Release: Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update DALLAS--(BUSINESS WIRE)--May 13, 2024-- Forte Biosciences, Inc. () (NASDAQ: FBRX), a clinical-stage biopharm